Abstract
A trial to evaluate the safety and immunogenicity of recombinant modified vaccinia Ankara (MVA) and fowlpox (FP) vectors expressing multiple HIV-1 proteins was conducted in twenty HIV-1 infected youth with suppressed viral replication on HAART. The MVA and FP-based multigene HIV-1 vaccines were safe and well tolerated. Increased frequencies of HIV-1 specific CD4+ proliferative responses and cytokine secreting cells were detected following immunization. Increased frequencies and breadth of HIV-1 specific CD8 T-cell responses were also detected. Plasma HIV-1-specific antibody levels and neutralizing activity were unchanged following vaccination. Poxvirus-based vaccines may merit further study in therapeutic vaccine protocols.
Publication types
-
Clinical Trial, Phase I
-
Multicenter Study
-
Research Support, N.I.H., Extramural
MeSH terms
-
AIDS Vaccines / adverse effects*
-
AIDS Vaccines / immunology*
-
Adolescent
-
Antiretroviral Therapy, Highly Active*
-
CD4 Lymphocyte Count
-
CD4-CD8 Ratio
-
Cytokines / biosynthesis
-
Female
-
Flow Cytometry
-
Fowlpox virus / immunology*
-
Gene Products, gag / biosynthesis
-
Gene Products, gag / genetics
-
HIV Antibodies / analysis
-
HIV Antibodies / biosynthesis
-
HIV Infections / drug therapy
-
HIV Infections / immunology*
-
HIV-1 / genetics
-
HIV-1 / immunology*
-
Humans
-
Interferon-gamma / biosynthesis
-
Male
-
Prospective Studies
-
RNA, Viral / analysis
-
RNA, Viral / biosynthesis
-
T-Lymphocytes / immunology
-
Vaccines, Synthetic / immunology
-
Vaccinia / immunology
-
Young Adult
Substances
-
AIDS Vaccines
-
Cytokines
-
Gene Products, gag
-
HIV Antibodies
-
RNA, Viral
-
Vaccines, Synthetic
-
Interferon-gamma